1. Volume 15, Issue 8, Pages 894-904 (July 2014)
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial 
Susan J Dutton, MSc, Prof David R Ferry, PhD, Prof Jane M Blazeby, MD, Haider Abbas, MRCP, Asa Dahle-Smith, MBChB, Wasat Mansoor, PhD, Joyce Thompson, FRCP, Mark Harrison, PhD, Anirban Chatterjee, FRCR, Stephen Falk, MD, Angel Garcia-Alonso, MD, David W Fyfe, MD, Richard A Hubner, PhD, Tina Gamble, Lynnda Peachey, BSc, Mina Davoudianfar, BA, Sarah R Pearson, BSc, Patrick Julier, MSc, Prof Janusz Jankowski, PhD, Rachel Kerr, MD, Russell D Petty, MRCP 
The Lancet Oncology 
Volume 15, Issue 8, Pages (July 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile PRO=patient-reported outcome.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Survival
Kaplan-Meier plots of overall survival by (A) treatment and (B) performance status, and (C) progression-free survival by treatment. HR=hazard ratio. PS=performance status.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Hazard ratio plot of the treatment effect by prognostic factors for progression-free survival
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

5. Figure 4
Waterfall plots for patients with measurable disease at baseline and 4 weeks, response confirmed at 8 weeks
Green=recorded as progressed by 8 weeks, might have been new lesions. Grey=not reported as progressed. RECIST=Response Evaluation Criteria in Solid Tumors.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

6. Figure 5
Mean raw scores for prespecified patient-reported outcomes at all timepoints
Higher score equates to better quality of life or more symptoms.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

7. Figure 6
Mean change in health-related quality-of-life outcomes from baseline to 4 weeks
Positive values on the functioning scale and negative values on the symptom scale denote benefit from gefitinib compared with placebo.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions